See the DrugPatentWatch profile for yervoy

Yervoy (ipilimumab) is a type of immunotherapy used to treat certain types of cancer, including melanoma. According to the drug's manufacturer, Bristol Myers Squibb, Yervoy can increase the risk of severe side effects [1].

Clinical trials have shown that Yervoy can cause severe immune-mediated side effects, which can affect various organs and systems in the body. These side effects can occur during treatment or even weeks or months after the last dose [1].

The most common severe side effects of Yervoy include:

* Immune-mediated enterocolitis (inflammation of the intestines)
* Hepatitis (inflammation of the liver)
* Dermatitis (inflammation of the skin)
* Neuropathy (nerve damage)
* Endocrinopathies (hormonal imbalances)

The exact increase in risk for severe side effects due to Yervoy is not explicitly stated in the available information. However, it is noted that the incidence of severe immune-mediated adverse reactions in patients treated with Yervoy is significantly higher than in those treated with a placebo [1].

It is important for patients to discuss the potential risks and benefits of Yervoy with their healthcare provider before starting treatment. Regular monitoring and reporting of any side effects to healthcare professionals is also crucial during and after Yervoy therapy [1].

Sources:

[1] Bristol Myers Squibb. "Yervoy (ipilimumab) Prescribing Information." Accessed on DrugPatentWatch.com on March 28, 2023. <https://drugpatentwatch.com/drugs/yervoy/prescribing-information>